Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis (Nasdaq: PSNL) launched Real-Time Variant Tracker, an early-access option for its ultrasensitive NeXT Personal molecular residual disease (MRD) blood test.
The Tracker adds optional reporting of emerging resistance and therapeutically targetable mutations, including ESR1 and hundreds of other clinically relevant mutations across solid tumors, to inform treatment decisions during MRD monitoring and surveillance. The option is available to physicians and biopharma partners through an Early Access Program (EAP).
Personalis (Nasdaq: PSNL) reported preliminary unaudited results for the year ended December 31, 2025, highlighting clinical and commercial progress and a strong cash position. Total 2025 revenue is expected to be $69.0M to $70.0M versus $84.6M in 2024. Clinical test volume reached ~16,233 tests in 2025 (≈+400% YoY) with clinical test revenue of ~$2.0M. Q4 revenue is preliminarily $17.0M to $18.0M, with Q4 clinical volume of 6,183 tests (+41% sequential) and clinical revenue ≈$0.9M. Core commercial streams (pharma/services/other) contributed ~$49M–$50M, and enterprise/population sequencing revenue totaled ≈$18.0M. The company ended 2025 with approximately $240.0M in cash, including ≈$109.0M net proceeds from an ATM program. Medicare coverage for breast cancer surveillance and peer‑reviewed publications were noted as strategic clinical milestones.
Personalis (Nasdaq: PSNL) announced publication of a study in Clinical Cancer Research demonstrating clinical utility of its NeXT Personal ultrasensitive, tumor-informed MRD ctDNA assay for monitoring immunotherapy across solid tumors.
The study analyzed 202 stage IV patients across 24 cancer types, tracking up to ~1,800 tumor-specific variants per patient. Key findings: baseline ctDNA detected in 98% of patients; early decreases in ctDNA were associated with significantly higher overall survival, while early increases correlated with a 0% overall response rate; and durable ctDNA clearance (negative for ≥180 days) corresponded to 100% overall survival in the cohort.
Personalis (Nasdaq: PSNL) announced a Cell publication reporting results from 431 stage I–III NSCLC patients in the TRACERx cohort, tracked a median of >5 years using the NeXT Personal ultrasensitive MRD test.
Key findings: the test showed exceptional sensitivity and specificity across diagnosis, post-surgery landmark, adjuvant therapy, and long-term surveillance; ~36–43% of detections were in the ultrasensitive range; cancer was detected a median of ~5–9 months (up to ~57 months) before imaging; failure to clear ctDNA during adjuvant chemo was associated with >5x higher relapse risk. The test uses whole-genome sequencing and proprietary noise suppression to detect ctDNA down to ~1 PPM.
Personalis (Nasdaq: PSNL) announced its management team will attend the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at the Lotte New York Palace in New York, NY.
The company will be represented by management at the conference to engage with investors and industry participants.
Personalis (Nasdaq: PSNL) announced Medicare coverage of its ultrasensitive NeXT Personal test for surveillance of breast cancer recurrence. Coverage applies to Medicare beneficiaries with stage II and III breast cancer (HR+/HER2-, HER2+, TNBC) for up to six years in the surveillance setting.
A published study reported NeXT Personal detected 100% of recurrent cases a median of ~15 months (and up to ~5 years) before radiographic imaging, and 100% of patients with consistently negative tests remained disease-free.
Personalis (Nasdaq: PSNL) reported Q3 2025 results on November 4, 2025, highlighting operational progress in its "Win‑in‑MRD" strategy and accelerating clinical adoption.
Key metrics: delivered 4,388 clinical tests (+26% sequential, +364% YoY); revenue $14.5M (down 44% vs $25.7M); gross margin 13.2% (vs 34.0%); net loss $21.7M or $0.24 per share; cash and short‑term investments $150.5M.
Commercial and clinical updates: submitted a third Medicare lung cancer dossier, presented NeoADAURA and LAURA trial data showing earlier MRD detection, and launched the CATE breast cancer utility study with Yale. Guidance: Q4 revenue $15.7–$20.7M; full‑year 2025 revenue $68.0–$73.0M (reduced); population sequencing guidance raised to $16.5–$17.0M; clinical test reimbursement now $1.5–$2.0M (reduced); gross margin guide 22–24%; expected full‑year net loss ≈$85M and cash usage ≈$75M.
Personalis (NASDAQ: PSNL) will release its third quarter 2025 financial results on Tuesday, November 4, 2025. A conference call and webcast to discuss results and recent highlights will be held the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Domestic callers may dial 877-451-6152; international callers may dial 201-389-0879. The live webinar is available via the Events section at investors.personalis.com, and a replay will be archived on the company's website shortly after the call.
Personalis (Nasdaq: PSNL) reported new analysis from the AstraZeneca phase 3 LAURA trial showing that the NeXT Personal® ultrasensitive MRD test can monitor maintenance treatment response after chemoradiotherapy in unresectable stage III, EGFR-mutated NSCLC.
Key findings: Osimertinib treatment led to MRD clearance in most patients with post-CRT MRD, and NeXT Personal detected MRD progression with a median 5-month lead time ahead of Blinded Independent Central Review (BICR) assessed progression. The LAURA results will be presented at ESMO 2025. Prior studies cited include CALLA (detection up to ~16 months before imaging) and NeoADAURA.
Personalis (Nasdaq: PSNL), a precision oncology genomics company, has granted inducement stock options to its newly appointed Senior Vice President and Chief Information Officer. The award includes options to purchase 440,000 shares of common stock at $5.93 per share under the company's 2020 Inducement Plan.
The stock options have a four-year vesting schedule, with 25% vesting after one year and the remaining vesting monthly over the following three years. This grant complies with Nasdaq Rule 5635(c)(4) for new employee equity incentives.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
